Clinical trial

Caratterizzazione Del Profilo Mutazionale Nel Tumore Papillare Della Tiroide Tramite Tecnologia Mass-ARRAY

Name
05C825
Description
Somatic mutations in the MAP (mitogen-activated protein) kinase pathway have been found in about 80% of papillary thyroid tumors (PTCs). The evaluation of the PTC mutational profile is crucial for the definition of the prognosis and for predicting the effects of targeted and personalized therapies. Molecular characterization by mass spectrometry (Mass ARRAY) allows the search for multiple mutations in a single experiment, in a sensitive, fast and economic way. A Mass ARRAY platform (PTC-MA) was developed, capable of identifying the presence of the most common somatic point mutations and rearrangements in PTC (Pesenti et al., Endocrine 2017). The aim of the study is to characterize the mutational profile of a large series of papillary thyroid carcinomas (PTC). Tumor samples will be analyzed using our PTC-MA platform. The molecular profile of PTCs will be correlated with the clinical and prognostic characteristics of the patients.
Trial arms
Trial start
2019-01-08
Estimated PCD
2027-10-30
Trial end
2027-12-31
Status
Recruiting
Treatment
Genotyping
Characterization of genetic profile of tumor tissues
Arms:
Patients with papillary thyroid cancer
Size
600
Primary endpoint
Mutational profile of PTCs
years 1-8
Eligibility criteria
Inclusion Criteria: * patients with papillary thyroid cancer * patients whose tumor tissue can be recovered for genetic analysis Exclusion Criteria: * patients who did not give consent * patients lost to follow-up * tumor samples not suitable for genetic analysis
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'papillary thyroid tumor tissue'}, 'enrollmentInfo': {'count': 600, 'type': 'ESTIMATED'}}
Updated at
2023-03-13

1 organization

1 product

1 indication

Product
Genotyping